Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
BO-112 plus pembrolizumab bij anti-PD-1-resistent gevorderd melanoom
aug 2025 | Dermato-oncologie, Immuuntherapie